Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue SUPPL. 1, 2011, Pages

  Freemantle, Nick ^a   Tharmanathan, Puvan ^a   Herbrecht, Raoul ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Empirical therapy pre emptive therapy; Invasive fungal disease; Randomized controlled trials

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CASPOFUNGIN; CONVENTIONAL AMPHOTERICIN B; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ACUTE LEUKEMIA; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; CANCER CHEMOTHERAPY; CLINICAL ASSESSMENT; DRUG RESPONSE; FEBRILE NEUTROPENIA; FUSARIUM; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOCOMPROMISED PATIENT; INVASIVE ASPERGILLOSIS; MIXED TREATMENT COMPARISON; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL; SYSTEMATIC REVIEW; SYSTEMIC MYCOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; ZYGOMYCOSIS;

ANTIFUNGAL AGENTS; CHEMOPREVENTION; FEVER OF UNKNOWN ORIGIN; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 78650530503     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq439     Document Type: Review

References (22)

1. Maertens J, Marchetti O, Herbrecht R et al. European Guidelines for antifungal management in leukaemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 2010; doi:10.1038/bmt.2010.175.
2. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-9.
3. Erjavec Z, Kluin-Nelemans H, Verweij PE. Trends in invasive fungal infections, with emphasis on invasive aspergillosis. Clin Microbiol Infect 2009; 15: 625-33.
4. Segal BH, Almyroudis NG, Battiwalla M et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007; 44: 402-9.
5. Herbrecht R, Berceanu A. Beta-D-glucan detection test: a step toward preemptive therapy for fungal infections in leukemic patients? Clin Infect Dis 2008; 46: 886-9.
6. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23: 3105-24.
7. Spiegelhalter DJ, Best NG, Carlin BP et al. Bayesian measures of model complexity and fit. J R Stat Soc Series B Stat Methodol 2002; 64: 1-34.
8. Boogaerts M, Winston DJ, Bow EJ et al. Itraconazole Neutropenia Study Group. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001; 135: 412-22.
9. Bowden R, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359-66.
10. Herbrecht R, Denning DW, Patterson TF et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
11. Leenders AC, Daenen S, Jansen RL et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998; 103: 205-12.
12. Prentice HG, Hann IM, Herbrecht R et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711-8.
13. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-71.
14. Walsh TJ, Pappas P, Winston DJ et al. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-34.
15. Erratum in: N Engl J Med 2007; 356: 760.
16. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
17. White MH, Bowden RA, Sandler ES et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27: 296-302.
18. Wingard JR, White MH, Anaissie E et al. L Amph/ABLC Collaborative Study Group. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31: 1155-63.
19. Hebart H, Klingspor L, Klingebiel T et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplant 2009; 43: 553-61.
20. Cordonnier C, Pautas C, Maury S et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48: 1042-51.
21. Maertens JA, Frère P, Lass-Flörl C et al. Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer 2007; 5:43-8.
22. Marchetti O, Cordonnier C, Calandra T. Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. EJC Supplements 2007; 5: 32-42.